- Orthocell’s (OCC) Remplir product is included on the Australian Prostheses List
- The company says inclusion in the list enables surgeons to receive reimbursement from private insurers for the use of Remplir in peripheral nerve repair procedures
- Orthocell’s Managing Director, Paul Anderson, says he’s delighted patients now have access to a premium nerve repair device that has been designed, manufactured and now reimbursed in Australia
- Inclusion on the Prostheses List follows the company gaining Australian market approval for Remplir in March, with Device Technologies nominated as the exclusive distributor of the product across Australia and New Zealand
- Orthocell shares are up 2.38 per cent to 43 cents at midday AEDT
Orthocell’s (OCC) Remplir product has been included on the Australian Prostheses List.
The company today said it had received the notification from the Australian Government Department of Health, with the inclusion in the list enabling surgeons to receive reimbursement from private insurers for the use of Remplir in peripheral nerve repair procedures. This in turn reduces costs to the patient.
Remplir is a collagen nerve wrap used to help repair peripheral nerve injuries. Orthocell said it believed Remplir would become a market-leading nerve repair device, driven by its ease of use and removing the need for damaging sutures for better patient outcomes.
Orthocell said the product had a “significant” market in Australia, with 11,7801 surgical repairs of peripheral nerves completed in public and private hospitals in the 2019/20 financial year.
“Inclusion of Remplir on the Prostheses List is the culmination of translational research and a regulatory program to bring this product to the Australian market,” Orthocell Managing Director Paul Anderson said.
“I am delighted that patients now have access to a premium nerve repair device that has been designed, manufactured and now reimbursed in Australia.”
Inclusion on the Prostheses List follows the company gaining Australian market approval for Remplir in March, with Device Technologies nominated as the exclusive distributor of the product across Australia and New Zealand.
Orthocell shares are up 2.38 per cent to 43 cents at midday AEDT.